References
- Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin for patients with Type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet [Internet]. 2010;375:1447–1456. doi:10.1016/S0140-6736(10)60307-8 Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673610603078
- Li H, Fang Y, Guo S, et al. GPR119 agonists for the treatment of Type 2 diabetes: an updated patent review (2014-present). Expert Opin Ther Pat [Internet]. 2021;31:795–808. doi:10.1080/13543776.2021.1921152
- Cheng C, Jabri S, Taoka BM, et al. Small molecule glucagon receptor antagonists: an updated patent review (2015–2019). Expert Opin Ther Pat [Internet]. 2020;30:509–526. doi:10.1080/13543776.2020.1769600
- Matoori S. Diabetes and its complications. ACS Pharmacol Transl Sci [Internet]. 2022;5:513–515. doi:10.1021/acsptsci.2c00122
- Artasensi A, Pedretti A, Vistoli G, et al. Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs. Molecules [Internet]. 2020;25:1987. doi:10.3390/molecules25081987 Available from: https://www.mdpi.com/1420-3049/25/8/1987
- Li H, Fang Y, Guo S, et al. GPR119 agonists for the treatment of Type 2 diabetes: an updated patent review (2014-present). Expert Opin Ther Pat [Internet]. 2021;31:795–808. doi:10.1080/13543776.2021.1921152
- Ohishi T, Yoshida S. The therapeutic potential of GPR119 agonists for Type 2 diabetes. Expert Opin Investig Drugs [Internet]. 2012;21:321–328. doi:10.1517/13543784.2012.657797
- Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev [Internet]. 2007;87:1409–1439. doi:10.1152/physrev.00034.2006
- Kieffer TJ, Francis Habener J. The Glucagon-Like Peptides. Endocr Rev [Internet]. 1999;20:876–913. doi:10.1210/edrv.20.6.0385 Available from: https://academic.oup.com/edrv/article/20/6/876/2530991
- Sisson EM. Liraglutide: clinical pharmacology and considerations for therapy. Pharmacotherapy. 2011;31:896–911. doi:10.1592/phco.31.9.896
- Damholt B, Golor G, Wierich W, et al. An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide. J Clin Pharmacol [Internet]. 2006;46:635–641. doi:10.1177/0091270006288215
- Dejgaard TF, Frandsen CS, Holst JJ, et al. Liraglutide for treating Type 1 diabetes. Expert Opin Biol Ther [Internet]. 2016;16:579–590. doi:10.1517/14712598.2016.1160050
- Brunton SA, Wysham CH. GLP-1 receptor agonists in the treatment of Type 2 diabetes: role and clinical experience to date. Postgrad Med [Internet]. 2020;132:3–14. doi:10.1080/00325481.2020.1798099
- Davies MJ, Kela R, Khunti K. Liraglutide - overview of the preclinical and clinical data and its role in the treatment of Type 2 diabetes. Diabetes, Obes Metab. 2011;13:207–220. doi:10.1111/j.1463-1326.2010.01330.x
- Ribel U, Larsen MO, Rolin B, et al. NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs. Eur J Pharmacol [Internet]. 2002;451:217–225. doi:10.1016/S0014-2999(02)02189-1 Available from: https://linkinghub.elsevier.com/retrieve/pii/S0014299902021891
- Larsen PJ, Fledelius C, Knudsen LB, et al. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes [Internet]. 2001;50:2530–2539. doi:10.2337/diabetes.50.11.2530 Available from: https://diabetesjournals.org/diabetes/article/50/11/2530/53891/Systemic-Administration-of-the-Long-Acting-GLP-1
- Noyan-Ashraf MH, Momen MA, Ban K, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes [Internet]. 2009;58:975–983. doi:10.2337/db08-1193 Available from: https://diabetesjournals.org/diabetes/article/58/4/975/118/GLP-1R-Agonist-Liraglutide-Activates
- Marre M, Shaw J, Brändle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med [Internet]. 2009;26:268–278. doi:10.1111/j.1464-5491.2009.02666.x
- Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in Type 2 diabetes. Diabetes Care [Internet]. 2009;32:84–90. doi:10.2337/dc08-1355 Available from: https://diabetesjournals.org/care/article/32/1/84/28994/Efficacy-and-Safety-Comparison-of-Liraglutide
- Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for Type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet [Internet]. 2009;373:473–481. doi:10.1016/S0140-6736(08)61246-5 Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673608612465
- Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with Type 2 diabetes (LEAD-4 Met + TZD). Diabetes Care [Internet]. 2009;32:1224–1230. doi:10.2337/dc08-2124 Available from: https://diabetesjournals.org/care/article/32/7/1224/26658/Efficacy-and-Safety-of-the-Human-Glucagon-Like
- Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in Type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Diabetologia [Internet]. 2009;52:2046–2055. doi:10.1007/s00125-009-1472-y
- Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for Type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet [Internet]. 2009;374:39–47. doi:10.1016/S0140-6736(09)60659-0 Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673609606590
- Jendle J, Nauck MA, Matthews DR, et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for Type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obes Metab [Internet]. 2009;11:1163–1172. doi:10.1111/j.1463-1326.2009.01158.x
- Seo Y-G. Side effects associated with liraglutide treatment for obesity as well as diabetes. J Obes Metab Syndr [Internet]. 2021;30:12–19. doi:10.7570/jomes20059
- Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-Cells causing calcitonin release and C-cell proliferation. Endocrinology [Internet]. 2010;151:1473–1486. doi:10.1210/en.2009-1272 Available from: https://academic.oup.com/endo/article/151/4/1473/2456651
- Release P. Glenmark is the first to launch biosimilar of popular anti - diabetic drug, Liraglutide, in India. 2024.
- 4. CN108191981. Preparation method of liraglutide intermediate polypeptide. 2019;153827.
- Puppala ML, Mudili V. 5. WO2019082138 - Process for preparation of liraglutide using recombinant. 2017;45996.
- Pharmaceuticals LEE, Baicheng Y, Yunxing Z. Bacterium capable of efficiently expressing liraglutide precursor and application of recombinant engineering. 11–12.
- Data PCTB. 5. WO2020053683. Process for production of soluble recombinant peptides. 77416.
- Data NB. Preparation method of GLP-1 analogue. 10–11.
- Data PCTB. 1. WO2016005960. Process for preparation of liraglutide. 1–8.
- Pradesh A, Katkam CIN, No H. Process for the preparation of liraglutide. 2014;29478.
- Carbajo D, Albericio F. Method for Preparation of Liraglutide using BAL Linker. 2017;3414257.
- Data PCTB. 6. WO2021152622. Improved process for the preparation of liraglutide. 2021;2–3.
- IN2536/CHE/2013. Process for the preparation of liraglutide. 2016;199397.
- Lonza AG. 9. EP3196206 - Method for preparation of. 2017;3196207.
- Data PCTB. 22. WO2018033127. Synthesis method for low-racemization impurity liraglutide. 2016;10–11.
- Data NB. 3. EP3551643. Synthesis of liraglutide. 2018;3551643.
- Mallesons W. 17. WO2021007703 - A method for preparing liraglutide via a solid phase peptide synthesis. 82827.
- Data PCTB. 51. WO2023279324. Method for synthesizing GLP-1 analog. 10–11.
- Data NB. 3. CN107827973. Solid phase synthetic method for liraglutide. 50–53.
- cn110615836. Solid-phase synthesis method of liraglutide. 82827.
- in3319/che/2015. Pharmaceutical formulations comprising liraglutide. 2017;23811.
- in201741047442. Liraglutide formulations for parenteral use. 23811.
- Multivesicular liposome and preparation. 46389.
- Analogue and application thereof in oral. 46389.
- CN115120564. Preparation process of liraglutide sustained-release microspheres. 19728.
- Exosome in preparation of drug carrier. 58734.
- Liraglutide Microneedle Patch application As Well As Preparation Method. 58734. Available from: https://patentimages.storage.googleapis.com/ec/5f/55/2c02d516991d25/US20180099018A1.pdf
- In preparation of drug for treating osteoporosis. 96814509.
- CN108245664. Application of liraglutide in treatment of periodontitis. 46389.
- CN111789939. Application of liraglutide in preparing tumor immnuo-therapy. 46389.
- CN110694052. Application of liraglutide in preparation of preparations for promoting peripheral. 46389.
- Phase N, Family P. Foot ulcer. 1–9.
- As immune cell therapy synergist. 58734.